Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Du H, Mallik L, Hwang D, Sun Y, Kaku C, Hoces D, Sun SM, Ghinnagow R, Carro SD, Phan HAT, Gupta S, Blackson W, Lee H, Choe CA, Dersh D, Liu J, Bell B, Yang H, Papadaki GF, Young MC, Zhou E, El Nesr G, Goli KD, Eisenlohr LC, Minn AJ, Hernandez-Lopez RA, Jardine JG, Sgourakis NG, Huang PS. Targeting peptide antigens using a multiallelic MHC I-binding system. Nat Biotechnol. 2025 Oct; 43(10):1683-1693.
-
King Z, Fraint E. Chimeric Antigen Receptor T-Cell Treatment in Children. Pediatr Rev. 2024 May 01; 45(5):301-302.
-
Zipper R, Loeb DM, Lee MA, Oliver-Krasinski J, Liszewski MC, Fraint E. Respiratory Failure Due to Idiopathic Pneumonia Syndrome in a Pediatric Patient After Recipient-derived Allogeneic Chimeric Antigen Receptor T-Cell Therapy. J Pediatr Hematol Oncol. 2023 08 01; 45(6):e775-e780.
-
Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, McLaughlin J, Nesterenko PA, Mao Z, Bangayan NJ, Wang R, Tran W, Yang HT, Wang Y, Xu Y, Obusan MB, Cheng D, Lee AH, Kadash-Edmondson KE, Champhekar A, Puig-Saus C, Ribas A, Prins RM, Seet CS, Crooks GM, Witte ON, Xing Y. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2221116120.
-
Staudt RE, Carlson RD, Snook AE. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer Biol Ther. 2022 12 31; 23(1):127-133.
-
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022 04 13; 14(640):eabn2231.
-
Roy I, Smilnak G, Burkart M, Hamilton E, Thorp K, Miyata S, Ma S, Pro B, Winter J, Gordon L, Karmali R. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022 04; 197(1):71-75.
-
Anikeeva N, Panteleev S, Mazzanti NW, Terai M, Sato T, Sykulev Y. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. J Biol Chem. 2021 09; 297(3):101033.
-
Banerjee R, Shah N, Dicker AP. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clin Cancer Inform. 2021 06; 5:668-678.
-
Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021 03; 27(3):419-425.